An antibody drug directed at the collagen receptor DDR1 helps to mitigate immune exclusion in a mouse model of triple-negative breast cancer, allowing T cells to flood in and slow tumor progression. A startup company called Parthenon Therapeutics has launched to advance the therapy into clinical development.

中文翻译：

---

涉及免疫排斥的胶原蛋白受体

针对胶原蛋白受体 DDR1 的抗体药物有助于减轻三阴性乳腺癌小鼠模型中的免疫排斥，使 T 细胞大量涌入并减缓肿瘤进展。一家名为 Parthenon Therapeutics 的初创公司已经启动，将这种疗法推向临床开发。